Microsoft PowerPoint - L00 Introduction
|
L00 Introduction |
1 |
|
L01.1 Case 1_Gambacorta |
7 |
|
L01.2 RC_brussels_case2_SC |
78 |
|
L02 assessing metastatic disease_Brown |
97 |
|
L03 Standard RT_Rödel |
144 |
|
L04 ESTRO Rectal chemoradiation_Rob Glynne Jones |
179 |
|
L05_Surgical concepts after CRT |
234 |
|
L06 ANAL CANCER - prognostic factors_nigel scott |
287 |
|
L7_L8_GBrownTNM ESTRO 2 |
316 |
|
L9 What information can be derived from ypTNM, TRG, CRM_N Scott |
431 |
|
L10 RT fractionation_R Glynne-Jones |
462 |
|
L11 Role of Brachytherapy in Rectal C_Haustermans |
526 |
|
L12 Dose constrains for organ at risk_Gambacorta |
559 |
|
L13 Planning_rectal ca_fiorino |
619 |
|
L14 IGRT_ART_fiorino |
657 |
|
L17_New chemo_Targeted_Rödel |
682 |
|
L18_RECTAL CANCER WAW after CRT_Cunningham |
711 |
|
L19 trials_Rob Glynne_Jones |
746 |
|
L21_Staging and restaging_GBrownSCC |
771 |
|
L22_What is considered standard of care for radiotherapy_Haustermans |
787 |
|
L23_ESTRO Rectal chemoradiation_R Glynne-Jones |
807 |
|
L24_Role of salvage surgery for non-responders _Cunnigham |
861 |
|
L25 Atlas and contouring guidelines for anal cancer RT_Haustermans |
890 |
|
L26a_anal canal_short_advanced case |
924 |
|
L26b_anal canal_short_early case |
928 |
|
L27_Planning_anal canal ca_fiorino |
931 |
|
L28 Anal Tox_MA Gambacorta |
951 |
|
L29 ANAL CANCER - prognostic factors_Nigel |
983 |
|
L30_Biomarker_Anal_cancer_CRodel |
1012 |
|
L31 Anal trials_Rob Glynne-Jones |
1043 |